The abstract is read at the publisher; the summary is JClub's.
In midipigs, pancreas-specific KRASG12D activation alone (KC) or with TP53R167H (KPC) generates PDAC with marked intra- and inter-tumour heterogeneity and early KRAS signalling changes.
- Why it matters: Clinically relevant large animal models are lacking, limiting study of early PDAC mechanisms and translation of therapeutic strategies.
- What they did: KC and KPC genetically engineered pigs were analyzed with histopathology, molecular profiling, single-cell transcriptomics, flow cytometry, and derived PoPaCa cell lines; exploratory drug screening tested gemcitabine, paclitaxel, RSL3, and trametinib.
- The result: KPC pigs showed accelerated progression with PanINs, invasive carcinoma, perineural invasion, and early lymphatic dissemination, while early lesions contained an organised immune landscape and drug responses including pronounced sensitivity to RSL3.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.